OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Most older adults with advanced cancer value quality of life over extending survival, but that preference may not translate to clinical care or outcomes.
Patient-reported outcome measures improve survival risk and quality of life for cancer patients, according to a study published Aug. 13 in JAMA Network Open. PROMs are self-reported statements from ...
Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...
Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...
SAN DIEGO, June 2, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained ...
There is a lack of systematic solutions to manage supportive care issues in racial/ethnic minorities (REM) receiving treatment for cancer. We developed and implemented an electronic patient-reported ...
Real-world assessment of treatment-related symptoms and associated burden among African American and Caucasian patients receiving chemotherapy in the US. Impact of clinical response and AEs on ...
How can biotech companies use patient-reported outcomes to bring better drugs forward for patients? Generally, patient-reported outcomes (PROs) provide complementary information to measured or ...
“It’s really hard to be a patient with cancer. Patients suffer a lot at home and don’t reach out,” Ethan Basch, MD, said. “Helping to have better communication to address their needs is really ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results